Target Information

Target General Infomation
Target ID
T69707
Former ID
TTDNC00646
Target Name
Proteasome
Target Type
Successful
Disease Ischemia-reperfusion injury [ICD10: I00-I99]
Multiple myeloma [ICD9: 203; ICD10: C90]
Multiple myeloma; Relapsed or refractory primary amyloidosis [ICD9:203, 277.3; ICD10: C90, E85]
Myeloma [ICD9: 203; ICD10: C90]
Non-hodgkin's lymphoma; Mantle cell lymphoma [ICD10: C859, C85]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Unspecified [ICD code not available]
Drugs and Mode of Action
Drug(s) Bortezomib Drug Info Approved Multiple myeloma [537129], [541528]
Carfilzomib Drug Info Approved Multiple myeloma [532210], [542445]
MLN9708 Drug Info Approved Multiple myeloma; Relapsed or refractory primary amyloidosis [524820], [543142]
Bortezomib Drug Info Phase 3 Non-hodgkin's lymphoma; Mantle cell lymphoma [537129], [541528]
Delanzomib Drug Info Phase 2 Myeloma [532908]
Marizomib Drug Info Phase 1 Solid tumours [550092]
ONX-0912 Drug Info Preclinical Solid tumours [548643]
PS-519 Drug Info Terminated Ischemia-reperfusion injury [546727]
Modulator Bortezomib Drug Info [556264]
Carfilzomib Drug Info [532210]
Delanzomib Drug Info [531739]
MG-101 Drug Info
MLN9708 Drug Info [530730]
ONX-0912 Drug Info [531139]
PS-519 Drug Info
Inhibitor Marizomib Drug Info [531339]
References
Ref 524820ClinicalTrials.gov (NCT02181413) A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant. U.S. National Institutes of Health.
Ref 532210Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
Ref 532908Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Curr Cancer Drug Targets. 2014;14(6):517-36.
Ref 537129New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
Ref 541528(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6391).
Ref 542445(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7420).
Ref 543142(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8450).
Ref 546727Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009964)
Ref 548643Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027317)
Ref 550092Clinical pipeline report, company report or official report of Triphase Accelerator .
Ref 530730Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80.
Ref 531139A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15.
Ref 531339Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84.
Ref 531739Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70.
Ref 532210Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
Ref 556264Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.